Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Alodox
Overview
What is Alodox?
The structural formula of doxycycline hyclate is:
with a molecular formula of (CHNOHCI)CHO.HO
and a molecular weight of 1025.89. The chemical designation for
doxycycline is 4-(dimethylamino)-1, 4, 4a, 5, 5a, 6, 11,
12a-octahydro-3, 5, 10, 12, 12a-pentahydroxy-6 -methyl-1,
11-dioxo-2-naphthacenecarboxamide monohydrochloride, compound with
ethyl alcohol (2:1), monohydrate.
Doxycycline hyclate is a yellow to light-yellow crystalline powder which is soluble in water.
Each
tablet for oral administration contains 23mg doxycycline hyclate
equivalent to 20 mg of doxycycline. In addition, each tablet contains
the following inactive ingredients: anhydrous lactose, carnauba wax,
croscarmellose sodium, hypromellose, magnesum stearate,
microcrystalline cellulose, poldextrose, polyethylene glycol, titanium
dioxide, and triacetin.
What does Alodox look like?
What are the available doses of Alodox?
Sorry No records found.
What should I talk to my health care provider before I take Alodox?
Sorry No records found
How should I use Alodox?
To reduce the development of drug-resistant bacteria and maintain the effectivenessof Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline HyclateTablets should be used only to treat or prevent infections that are proven or stronglysuspected to be caused by susceptible bacteria. When culture and susceptibilityinformation are available, they should be considered in selecting or modifyingantibacterial therapy. In the absence of such data, local epidemiology andsusceptibility patterns may contribute to the empiric selection of therapy.Doxycycline hyclate is indicated for use as an adjunct to scaling and root planing topromote attachment level gain and to reduce pocket depth in patients with adultperiodontitis.
THE DOSAGE OF DOXYCYCLINE HYCLATE TABLETS DIFFERS FROM THATOF DOXYCYCLINE USED TO TREAT INFECTIONS. EXCEEDING THERECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OFSIDE EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANTMICROORGANISMS.Doxycycline hyclate tablets 20 mg twice daily as an adjunct following scaling androot planing may be administered for up to 9 months. Doxycycline hyclate tabletsshould be taken twice daily at 12 hour intervals, usually in the morning and evening.It is recommended that if doxycycline hyclate tablets is taken close to meal times,allow at least one hour prior to or two hours after meals. Safety beyond 12 monthsand efficacy beyond 9 months have not been established.
What interacts with Alodox?
Sorry No Records found
What are the warnings of Alodox?
Sorry No Records found
What are the precautions of Alodox?
Sorry No Records found
What are the side effects of Alodox?
Sorry No records found
What should I look out for while using Alodox?
This drug is contraindicated in persons who have shown hypersensitivity todoxycycline or any of the other tetracyclines.
THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTHDEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TOTHE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THETEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common duringlong-term use of the drugs but has been observed following repeated short termcourses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS,THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP AND INPREGNANT OR NURSING MOTHERS UNLESS THE POTENTIAL BENEFITSMAY BE ACCEPTABLE DESPITE THE POTENTIAL RISKS
All tetracyclines form a stable calcium complex in any bone forming tissue. Adecrease in fibula growth rate has been observed in premature infants given oraltetracyclines in doses of 25 mg/kg every 6 hours. This reaction was shown to bereversible when the drug was discontinued.
Doxycycline can cause fetal harm when administered to a pregnant woman. Resultsof animal studies indicate that tetracyclines cross the placenta, are found in fetaltissues, and can have toxic effects on the developing fetus (often related toretardation of skeletal development). Evidence of embryotoxicity has also beennoted in animals treated early in pregnancy. If any tetracyclines are used duringpregnancy, or if the patient becomes pregnant while taking this drug, the patientshould be apprised of the potential hazard to the fetus.
The catabolic action of the tetracyclines may cause an increase in BUN. Previousstudies have not observed an increase in BUN with the use of doxycycline inpatients with impaired renal function.
Photosensitivity manifested by an exaggerated sunburn reaction has been observedin some individuals taking tetracyclines. Patients apt to be exposed to direct sunlightor ultraviolet light should be advised that this reaction can occur with tetracyclinedrugs, and treatment should be discontinued at the first evidence of skin erythema.
What might happen if I take too much Alodox?
In case of
overdosage, discontinue medication, treat symptomatically and institute
supportive measures. Dialysis does not alter serum half-life and thus
would not be of benefit in treating cases of overdose.
How should I store and handle Alodox?
Storage and HandlingStore at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).Storage and HandlingStore at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).Doxycycline hyclate tablets USP equivalent to 20 mg of doxycycline, round, white,unscored, film coated tablet, debossed MP 573 on one side and blank on the otherside.Bottles of 60 NDC 54799-533-60Store at 20° to 25°C (68° to 77°F)[See USP Controlled Room Temperature]DISPENSE IN A TIGHT, LIGHT-RESISTANT CONTAINER.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
After oral administration, doxycycline hyclate is
rapidly and nearly completely absorbed from the gastrointestinal
tract. Doxycycline is eliminated with a half-life of approximately 18
hours by renal and fecal excretion of unchanged drug.
Non-Clinical Toxicology
This drug is contraindicated in persons who have shown hypersensitivity todoxycycline or any of the other tetracyclines.THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTHDEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TOTHE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THETEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common duringlong-term use of the drugs but has been observed following repeated short termcourses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS,THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP AND INPREGNANT OR NURSING MOTHERS UNLESS THE POTENTIAL BENEFITSMAY BE ACCEPTABLE DESPITE THE POTENTIAL RISKS All tetracyclines form a stable calcium complex in any bone forming tissue. Adecrease in fibula growth rate has been observed in premature infants given oraltetracyclines in doses of 25 mg/kg every 6 hours. This reaction was shown to bereversible when the drug was discontinued. Doxycycline can cause fetal harm when administered to a pregnant woman. Resultsof animal studies indicate that tetracyclines cross the placenta, are found in fetaltissues, and can have toxic effects on the developing fetus (often related toretardation of skeletal development). Evidence of embryotoxicity has also beennoted in animals treated early in pregnancy. If any tetracyclines are used duringpregnancy, or if the patient becomes pregnant while taking this drug, the patientshould be apprised of the potential hazard to the fetus. The catabolic action of the tetracyclines may cause an increase in BUN. Previousstudies have not observed an increase in BUN with the use of doxycycline inpatients with impaired renal function. Photosensitivity manifested by an exaggerated sunburn reaction has been observedin some individuals taking tetracyclines. Patients apt to be exposed to direct sunlightor ultraviolet light should be advised that this reaction can occur with tetracyclinedrugs, and treatment should be discontinued at the first evidence of skin erythema.
Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations. Theophylline only rarely alters the pharmacokinetics of other drugs.
The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with theophylline. The information in the “Effect” column of Table II assumes that the interacting drug is being added to a steady-state theophylline regimen. If theophylline is being initiated in a patient who is already taking a drug that inhibits theophylline clearance (e.g., cimetidine, erythromycin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be smaller. Conversely, if theophylline is being initiated in a patient who is already taking a drug that enhances theophylline clearance (e.g., rifampin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be larger. Discontinuation of a concomitant drug that increases theophylline clearance will result in accumulation of theophylline to potentially toxic levels, unless the theophylline dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits theophylline clearance will result in decreased serum theophylline concentrations, unless the theophylline dose is appropriately increased.
The drugs listed in Table III have either been documented not to interact with theophylline or do not produce a clinically significant interaction (i.e., <15% change in theophylline clearance).
The listing of drugs in Tables II and III are current as of February 9, 1995. New interactions are continuously being reported for theophylline, especially with new chemical entities. Before addition of a newly available drug in a patient receiving theophylline, the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and theophylline has been reported.
General:
The following adverse reactions have beenobserved in patients receiving tetracyclines:Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia,enterocolitis, and inflammatory lesions (with vaginal candidiasis) in the anogenitalregion. Hepatotoxicity has been reported rarely. Rare instances of esophagitis andesophageal ulcerations have been reported in patients receiving the capsule formsof the drugs in the tetracycline class. Most of these patients took medicationsimmediately before going to bed. (See DOSAGE AND ADMINISTRATION Section).Skin: maculopapular and erythematous rashes. Exfoliative dermatitis has beenreported but is uncommon. Photosensitivity is discussed above. (See WARNINGSSection).Renal toxicity: Rise in BUN has been reported and is apparently dose related. (SeeWARNINGS Section).Hypersensitivity reactions: urticaria, angioneurotic edema, anaphylaxis,anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemiclupus erythematosus.Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia havebeen reported.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).